

---

# CT-guided cryoablation of renal masses

---

FROM THE SPECIALTIES

JENS BORGBJERG

[jb@castlemountain.dk](mailto:jb@castlemountain.dk)

Jens Borgbjerg, PhD, senior consultant at the Department of Radiology, Akershus University Hospital.

The author has completed the ICMJE form and declares no conflicts of interest.

TONE KONGSRUD

Tone Kongsrud, senior consultant at the Department of Urology, Akershus University Hospital.

The author has completed the ICMJE form and declares no conflicts of interest.

ANNE NEGÅRD

Anne Negård, PhD, head senior consultant at the Department of Radiology, Akershus University Hospital, and professor II at the University of Oslo.

The author has completed the ICMJE form and declares no conflicts of interest.

NINA MICHELLE ROLLAND KROGH

Nina Michelle Rolland Krogh, radiographer and head of the Department of Radiology, Akershus University Hospital.

The author has completed the ICMJE form and declares no conflicts of interest.

THOMAS GÜNTHER

Thomas Günther, senior consultant at the Department of Anaesthetics, Akershus University Hospital.

The author has completed the ICMJE form and declares no conflicts of interest.

Stig Müller, PhD, head senior consultant at the Department of Urology, Akershus University Hospital, and associate professor at the University of Oslo.

The author has completed the ICMJE form and declares no conflicts of interest.

---

## **CT-guided cryoablation is offered at Akershus University Hospital to patients with benign and malignant renal masses.**

Patients with small renal masses ( $\leq 4$  cm) have traditionally been treated with nephrectomy or nephron-sparing surgery in the form of partial nephrectomy. Norwegian and international clinical guidelines now include thermal ablation as a treatment option for renal cancer [\(1, 2\)](#). Furthermore, Norway's clinical guidelines for cancer surgery recommend that health trusts performing surgery for renal cancer establish ablation treatment [\(3\)](#).

Thermal ablation involves using heat (radiofrequency ablation or microwave ablation) or extreme cold (cryoablation) to destroy tumour cells, with one or more thin needles being inserted into a renal mass. In cryoablation, argon gas circulates in the needles, creating temperatures as low as  $-180^{\circ}\text{C}$  and forming an 'ice ball' that encapsulates the tumour along with a surrounding margin of 0.5–1 cm.

Over the past two decades, various methods of cryoablation have been used, including open surgical access, as well as laparoscopic and percutaneous image-guided approaches. Longitudinal data from retrospective cohort studies has documented the advantages of CT-guided ablation. These include limiting local tumour progression, improving cancer-specific survival, reducing complication rates, enhancing renal function preservation, shortening the recovery period and cost-effectiveness [\(4, 5\)](#).

In general, thermal ablation is particularly attractive for patients who are deemed unable to tolerate surgery or who require less invasive treatment. Ablation should also be considered for patients where preservation of renal function is crucial, such as those with existing chronic kidney disease, a single kidney, metachronous tumours, or hereditary kidney cancer.

Compared to thermal ablation treatments, cryoablation allows for precise monitoring of the ablation zone (the ice ball) using CT imaging and is safer for treating tumours larger than 3 cm located near the renal hilum [\(6\)](#).

Since 2023, Akershus University Hospital has offered CT-guided cryoablation for renal masses to selected patients. The urology, anaesthesiology and radiology departments have developed this treatment provision based on the model used at Aarhus University Hospital in Denmark, where over 200 kidney tumour ablations are performed annually.

One of the challenges in establishing CT-guided cryoablation is achieving a sufficient patient volume. Studies evaluating the learning curve for tumour ablation suggest that performing at least 25 ablations per year is necessary to maintain and further develop expertise (7). Since transitioning from the project to the operational phase after one year, we have treated 27 patients with a total of 30 renal masses. Patients are typically discharged the day after the procedure, but this could eventually become a day surgery procedure. Our initial results have been satisfactory and align with findings in the international research literature (4).

The method has been well received internally within our hospital trust. We believe this method has the potential to benefit even more patients, including those outside our catchment area who are candidates for and seek minimally invasive treatment.

---

## REFERENCES

1. Helsedirektoratet. Nyrekreft – handlingsprogram. <https://www.helsedirektoratet.no/retningslinjer/nyrecellekreft-handlingsprogram> Accessed 7.11.2024.
2. Jiang P, Ali SN, Peta A et al. A Review of the Recommendations and Strength of Evidence for Clinical Practice Guidelines on the Management of Small Renal Masses. *J Endourol* 2023; 37: 903–13. [PubMed][CrossRef]
3. Helsedirektoratet. Organspesifikke råd. <https://www.helsedirektoratet.no/faglige-rad/kreftkirurgi--kompetanse-og-kvalitet/organspesifikke-rad> Accessed 7.11.2024.
4. Yanagisawa T, Mori K, Kawada T et al. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. *Urol Oncol* 2022; 40: 315–30. [PubMed][CrossRef]
5. Garcia RG, Katz M, Falsarella PM et al. Percutaneous Cryoablation versus Robot-Assisted Partial Nephrectomy of Renal T1A Tumors: a Single-Center Retrospective Cost-Effectiveness Analysis. *Cardiovasc Intervent Radiol* 2021; 44: 892–900. [PubMed][CrossRef]
6. Deivasigamani S, Adams ES, Séguier D et al. Cryoablation for the management of Small Renal Masses. *Mini Invasive Surg* 2023; 7: 9. [CrossRef]
7. Poon RT, Ng KK, Lam CM et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. *Ann Surg* 2004; 239: 441–9. [PubMed][CrossRef]

---

Publisert: 18 Desember 2024. Tidsskr Nor Legeforen. DOI: 10.4045/tidsskr.24.0542  
Received 14.10.2024, accepted 7.11.2024.  
Copyright: © Tidsskriftet 2026 Downloaded from tidsskriftet.no 19 June 2026.